Overview

Amivantamab in Adenoid Cystic Carcinoma

Status:
Not yet recruiting

Trial end date:
2028-12-01

Target enrollment:

Participant gender:

Summary

The purpose of the study is to determine if treatment with amivantamab will be efficacious in patients with recurrent and metastatic adenoid cystic carcinoma.

Phase:

Phase 2

Details

Lead Sponsor:

Trisha Wise-Draper